Most of the exposure to misinformation about cancer treatment occurs in conversations with family and friends and on social ...

SCAN Health Plan will expand its 2026 Medicare Advantage benefits with $0 copays and higher dental, vision and allowance ...

Rhapsido is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved for chronic spontaneous urticaria (CSU).

Pfizer only offered to discount six products through the Most Favored Nation program, and healthcare policy experts suggest the real-world impact remains uncertain.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

In a recent trial, verapamil showed a trend toward preserving insulin-producing beta cells in patients with Type 1 diabetes but failed to achieve statistical significance.